Production of glycoprotein vaccines in Escherichia coli

Microbial Cell Factories

Volumn 9, Issue , 2010, Pages

  Ihssen, Julian ^a   Kowarik, Michael ^b   Dilettoso, Sandro ^a   Tanner, Cyril ^b   Wacker, Michael ^b   Thöny Meyer, Linda ^a  

^a SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

^b GlycoVaxyn AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GLYCEROL; GLYCOCONJUGATE; GLYCOPROTEIN VACCINE; O ANTIGEN; PROTEIN ACRA; PROTEIN PGIB; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN; SHIGELLA VACCINE; TRANSFERASE; UNCLASSIFIED DRUG; ACRA PROTEIN, E COLI; BACTERIAL TOXIN; ESCHERICHIA COLI PROTEIN; GLYCOPROTEIN; HYBRID PROTEIN; LIPOPROTEIN; VACCINE;

ARTICLE; BACTERIAL CELL; CAMPYLOBACTER JEJUNI; CELL GROWTH; CONTROLLED STUDY; ESCHERICHIA COLI; GROWTH INHIBITION; MICROBIAL BIOMASS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PSEUDOMONAS AERUGINOSA; SHIGELLA DYSENTERIAE; VACCINE PRODUCTION; BIOSYNTHESIS; GENETICS; GLYCOSYLATION; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM;

BACTERIA (MICROORGANISMS); CAMPYLOBACTER JEJUNI; ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA; SHIGELLA; SHIGELLA DYSENTERIAE;

BACTERIAL TOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GLYCOPROTEINS; GLYCOSYLATION; LIPOPROTEINS; MEMBRANE TRANSPORT PROTEINS; O ANTIGENS; RECOMBINANT FUSION PROTEINS; SHIGELLA DYSENTERIAE; SHIGELLA VACCINES; VACCINES, CONJUGATE;

EID: 77955370642     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-9-61     Document Type: Article

References (48)

1. Anderson P. Antibody responses to Haemophilus influenzae type B and diphtheria toxin induced by conjugates of oligosaccharides of the type B capsule with the nontoxic protein Crm197. Infect Immun 1983, 39(1):233-238. 347931, 6600444.
2. Taylor DN, Trofa AC, Sadoff J, Chu CY, Bryla D, Shiloach J, Cohen D, Ashkenazi S, Lerman Y, Egan W, Schneerson R, Robbins JB. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 1993, 61(9):3678-3687. 281064, 8359890.
3. Robbins JB, Schneerson R, Szu SC, Pozsgay V. Bacterial polysaccharide-protein conjugate vaccines. Pure Appl Chem 1999, 71(5):745-754.
4. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res 2003, 338(23):2539-2547. 10.1016/j.carres.2003.07.008, 14670715.
5. Lockhart S. Conjugate vaccines. Expert Rev Vaccines 2003, 2(5):633-648. 10.1586/14760584.2.5.633, 14711325.
6. Messner P. Bacterial glycoproteins. Glycoconj J 1997, 14(1):3-11. 10.1023/A:1018551228663, 9076508.
7. Szymanski CM, Yao RJ, Ewing CP, Trust TJ, Guerry P. Evidence for a system of general protein glycosylation in Campylobacter jejuni. Mol Microbiol 1999, 32(5):1022-1030. 10.1046/j.1365-2958.1999.01415.x, 10361304.
8. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, Panico M, Morris HR, Dell A, Wren BW, Aebi M. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002, 298(5599):1790-1793. 10.1126/science.298.5599.1790, 12459590.
9. Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 2005, 102(8):3016-3021. 10.1073/pnas.0500044102, 549450, 15703289.
10. Wacker M, Feldman MF, Callewaert N, Kowarik M, Clarke BR, Pohl NL, Hernandez M, Vines ED, Valvano MA, Whitfield C, Aebi M. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc Natl Acad Sci USA 2006, 103(18):7088-7093. 10.1073/pnas.0509207103, 1459022, 16641107.
11. Kowarik M, Young NM, Numao S, Schulz BL, Hug I, Callewaert N, Mills DC, Watson DC, Hernandez M, Kelly JF, Wacker M, Aebi M. Definition of the bacterial N-glycosylation site consensus sequence. EMBO J 2006, 25(9):1957-1966. 10.1038/sj.emboj.7601087, 1456941, 16619027.
12. Kowarik M, Numao S, Feldman MF, Schulz BL, Callewaert N, Kiermaier E, Catrein I, Aebi M. N-linked glycosylation of folded proteins by the bacterial oligosaccharyltransferase. Science 2006, 314(5802):1148-1150. 10.1126/science.1134351, 17110579.
13. Riesenberg D, Schulz V, Knorre WA, Pohl HD, Korz D, Sanders EA, Ross A, Deckwer WD. High cell-density cultivation of Escherichia coli at controlled specific growth rate. J Biotechnol 1991, 20(1):17-28. 10.1016/0168-1656(91)90032-Q, 1367313.
14. Lee SY. High cell-density culture of Escherichia coli. Trends Biotechnol 1996, 14(3):98-105. 10.1016/0167-7799(96)80930-9, 8867291.
15. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77(8):651-666. 2557719, 10516787.
16. Niyogi SK. Shigellosis. J Microbiol 2005, 43(2):133-143.
17. Kweon MN. Shigellosis: the current status of vaccine development. Curr Opin Infect Dis 2008, 21(3):313-318. 10.1097/QCO.0b013e3282f88b92, 18448978.
18. Fält IC, Mills D, Schweda EKH, Timmis KN, Lindberg AA. Construction of recombinant aroA salmonellae stably producing the Shigella dysenteriae serotype 1 O-antigen and structural characterization of the Salmonella/Shigella hybrid LPS. Microb Pathog 1996, 20(1):11-30. 10.1006/mpat.1996.0002, 8692007.
19. Daniels MJ, Barber CE, Turner PC, Sawczyc MK, Byrde RJW, Fielding AH. Cloning of genes involved in pathogenicity of Xanthomonas campestris Pv campestris using the broad host range cosmid pLAFR1. EMBO J 1984, 3(13):3323-3328. 557857, 16453595.
20. Vanbleu E, Marchal K, Vanderleyden J. Genetic and physical map of the pLAFR1 vector. DNA Seq 2004, 15(3):225-227.
21. Dykxhoorn DM, StPierre R, Linn T. A set of compatible tac promoter expression vectors. Gene 1996, 177(1-2):133-136. 10.1016/0378-1119(96)00289-2, 8921858.
22. Ihssen J, Egli T. Specific growth rate and not cell density controls the general stress response in Escherichia coli. Microbiology 2004, 150:1637-1648. SGM, 10.1099/mic.0.26849-0, 15184550.
23. Egli T. Nutrition of microorganisms. Encyclopedia of Microbiology 2000, 3:431-447. San Diego, USA: Academic Press, 2.
24. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002, 71:635-700. 10.1146/annurev.biochem.71.110601.135414, 2569852, 12045108.
25. Soupene E, van Heeswijk WC, Plumbridge J, Stewart V, Bertenthal D, Lee H, Prasad G, Paliy O, Charernnoppakul P, Kustu S. Physiological studies of Escherichia coli strain MG1655: growth defects and apparent cross-regulation of gene expression. J Bacteriol 2003, 185(18):5611-5626. 10.1128/JB.185.18.5611-5626.2003, 193769, 12949114.
26. Rhee JI, Bode J, DiazRicci JC, Poock D, Weigel B, Kretzmer G, Schugerl K. Influence of the medium composition and plasmid combination on the growth of recombinant Escherichia coli JM109 and on the production of the fusion protein EcoRI::SPA. J Biotechnol 1997, 55(2):69-83. 10.1016/S0168-1656(97)00058-8, 9232030.
27. Berney M, Weilenmann HU, Ihssen J, Bassin C, Egli T. Specific growth rate determines the sensitivity of Escherichia coli to thermal, UVA, and solar disinfection. Appl Environ Microbiol 2006, 72(4):2586-2593. 10.1128/AEM.72.4.2586-2593.2006, 1449012, 16597961.
28. Donovan RS, Robinson CW, Glick BR. Optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter. J Ind Microbiol 1996, 16(3):145-154. 10.1007/BF01569997, 8652113.
29. Sevastsyanovich Y, Alfasi S, Overton T, Hall R, Jones J, Hewitt C, Cole J. Exploitation of GFP fusion proteins and stress avoidance as a generic strategy for the production of high-quality recombinant proteins. FEMS Microbiol Lett 2009, 299(1):86-94.
30. Pirt SJ. Principles of microbe and cell cultivation. 1975, Oxford: Blackwell Scientific Publications.
31. Guzman LM, Belin D, Carson MJ, Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol 1995, 177(14):4121-4130. 177145, 7608087.
32. Epstein W, Rothmandenes LB, Hesse J. Adenosine 3'-5'-cyclic monophosphate as mediator of catabolite repression in Escherichia coli. Proc Natl Acad Sci USA 1975, 72(6):2300-2304. 10.1073/pnas.72.6.2300, 432745, 166384.
33. Li ZP, Zhang X, Tan TW. Lactose-induced production of human soluble B lymphocyte stimulator (hsBLyS) in E. coli with different culture strategies. Biotechnol Lett 2006, 28(7):477-483. 10.1007/s10529-006-0002-y, 16614929.
34. Fält IC, Schweda EKH, Klee S, Singh M, Floderus E, Timmis KN, Lindberg AA. Expression of Shigella dysenteriae serotype-1 O-antigenic polysaccharide by Shigella flexneri aroD vaccine candidates and different Shigella flexneri serotypes. J Bacteriol 1995, 177(18):5310-5315. 177324, 7545156.
35. Sanden AM, Prytz I, Tubulekas I, Forberg C, Le H, Hektor A, Neubauer P, Pragai Z, Harwood C, Ward A, Picon A, Teixeira de Mattos J, Postma P, Farewell A, Nyström T, Reeh S, Pedersen S, Larsson G. Limiting factors in Escherichia coli fed-batch production of recombinant proteins. Biotechnol Bioeng 2003, 81(2):158-166. 10.1002/bit.10457, 12451552.
36. Neubauer P, Lin HY, Mathiszik B. Metabolic load of recombinant protein production: inhibition of cellular capacities for glucose uptake and respiration after induction of a heterologous gene in Escherichia coli. Biotechnol Bioeng 2003, 83(1):53-64. 10.1002/bit.10645, 12740933.
37. Hoffmann F, Rinas U. Stress induced by recombinant protein production in Escherichia coli. Adv Biochem Eng Biotechnol 2004, 89:73-92.
38. Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E, Baumann K, Giuliani M, Parrilli E, Branduardi P, Lang C, Porro D, Ferrer P, Tutino ML, Mattanovich D, Villaverde A. Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact 2008, 7:11. 10.1186/1475-2859-7-11, 2322954, 18394160.
39. Wagner S, Bader ML, Drew D, de Gier JW. Rationalizing membrane protein overexpression. Trends Biotechnol 2006, 24(8):364-371. 10.1016/j.tibtech.2006.06.008, 16820235.
40. Sorensen HP, Mortensen KK. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact 2005, 4:1. 10.1186/1475-2859-4-1, 544838, 15629064.
41. Amann E, Ochs B, Abel KJ. Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli. Gene 1988, 69(2):301-315. 10.1016/0378-1119(88)90440-4, 3069586.
42. Curless C, Pope J, Tsai L. Effect of preinduction specific growth rate on recombinant alpha consensus interferon synthesis in Escherichia coli. Biotechnol Prog 1990, 6(2):149-152. 10.1021/bp00002a009, 1366547.
43. Hoffmann F, van den Heuvel J, Zidek N, Rinas U. Minimizing inclusion body formation during recombinant protein production in Escherichia coli at bench and pilot plant scale. Enzyme Microb Technol 2004, 34(3-4):235-241.
44. Keith PM, Cain WJ. Fermentation process for the high level production of bovine growth hormone. United States Patent 1988, No. 4762784..
45. Strandberg L, Kohler K, Enfors SO. Large-scale fermentation and purification of a recombinant protein from Escherichia coli. Process Biochem 1991, 26(4):225-234.
46. Panda AK, Khan RH, Rao KBCA, Totey SM. Kinetics of inclusion body production in batch and high cell density fed-batch culture of Escherichia coli expressing ovine growth hormone. J Biotechnol 1999, 75(2-3):161-172. 10.1016/S0168-1656(99)00157-1, 10553655.
47. Passwell JH, Harlev E, Ashkenazi S, Chu CY, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001, 69(3):1351-1357. 10.1128/IAI.69.3.1351-1357.2001, 98027, 11179298.
48. Miroux B, Walker JE. Over-production of proteins in Escherichia coli: Mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J Mol Biol 1996, 260(3):289-298. 10.1006/jmbi.1996.0399, 8757792.